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Medication-Induced Oculomotor Dysfunction: a report of two cases
Abstract
Background: Consideration of current medications and their interactions as a source of new onset
oculomotor dysfunction is imperative for providing good eye care. Medication etiology should be
particularly suspected when the symptoms begin with the initiation of a new medication and resolved
with discontinuation of the same medication.
Case Reports: Presented are two cases demonstrating that it is prudent to be aware of medications
capable of inducing oculomotor dysfunction. Each case reveals instances of acute oculomotor
dysfunction after the initiation of a central nervous system affecting medication. Case 1 details a partial
pupil sparing third nerve palsy after initiating the anti-anxiety drug, buspirone. Case 2 accounts the
addition of zolpidem (Ambien), a sedative, and the subsequent new onset nystagmus and hypertropia.
Conclusion: In each case, no organic etiology was found, and the oculomotor dysfunction resolved
following discontinuation of the recently added CNS affecting medication. Specific drug interactions are
also considered as contributing factors to the oculomotor dysfunction in both cases.
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Background
New onset diplopia and nystagmus are sure to grab the attention of patients and
providers alike. Havoc is wreaked upon the patient’s visual status and the provider
realizes the etiology may be sinister and challenging to elucidate. Context is king
when determining the urgency of the case and what steps are needed to uncover the
cause of the oculomotor dysfunction. Patient medical history must be thoroughly
investigated, including cardiovascular disease (i.e. diabetes, hypertension,
aneurysms and cerebral vascular accidents), primary and metastatic cancer, thyroid
disease, infections, neuropathies (i.e. Multiple Sclerosis and Myasthenia Gravis)
and inflammatory disease (i.e. giant cell arteritis)1,2,3,4. Relevant patient ocular
history may include recent ocular trauma (i.e. blow-out fracture), past strabismus
surgery or an established need for prismatic spectacle correction1,2,3. The clinician
must consider simultaneously occurring associated factors, such as headache,
eyelid ptosis, pupil dysfunction, optic neuropathy and other neurological signs (i.e.
unilateral weakness or numbness, slurred speech, dizziness, nausea and altered
mental status) as clues to organic etiologies1,2,3. Additionally, as demonstrated in
the presented cases, side effects of current medications and/or medication
interactions should be considered when presented with a case of new onset
oculomotor dysfunction, especially when the onset of symptoms coincides with the
initiation of a new drug 4,5,6.
CASE 1
A 65-year-old black male presented with a chief complaint of a constant inability
to open his left eye with a sudden onset three days prior. No injury, pain, headache,
double vision, nor blurry vision of the right eye were reported. He stated
compliance with all prescribed medications and denied illicit drug use. Patient
medical history was positive for insulin dependent diabetes (7 years duration),
hypertension, hyperlipidemia, stroke, and anxiety. Patient ocular history was
essentially non-contributory, being negative for past ocular surgeries, major
injuries and ocular pathology. The patient had a positive history of cigarette
smoking (discontinued 1 year previously) and recreational drug use (cocaine and
marijuana, both discontinued multiple years earlier). The patient was unsure of his
last blood glucose level, but his last HbA1c was 6.3% a month prior. Blood pressure
measured 180/100 mmHg at his primary care provider’s exam three weeks before
presenting for this vision examination. The primary care provider’s plan for
addressing the high blood pressure was to continue the hydralazine and change the
lisinopril to lisinopril/hydrochlorothiazide. Also, of note, the primary care provider
added buspirone to address the patient’s increased anxiety.
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The corrected distance acuities were 20/20- and 20/25+ in the right and left eye
(upon manually lifting the left upper eyelid) respectively. These acuities were stable
compared to his last eye exam one month prior. There was a complete ptosis of the
left upper eye lid. Confrontation visual fields were normal for each eye, and no
pupillary defect was observed. The patient did, however, have restricted ocular
movement to superior gaze of the left eye.
The patient’s clinic picture at this visit was consistent with a painless, left,
incomplete, isolated, pupil sparing, superior division ocular motor (CNIII) nerve
palsy. In the context of vascular disease history, no reported headache, and no pupil
involvement, a one-week follow-up visit with no additional ancillary testing is often
appropriate. The exception to this general follow-up period is a superior division
CNIII palsy, as this specific presentation is often the result of a space-occupying
lesion3. Therefore, even though no pupil abnormalities were evident at this initial
encounter, a head CT scan was ordered. Compliance with all medications was
stressed, and the patient was instructed to contact the clinic with any new or
worsening of symptoms. The examination findings were shared with the primary
care provider with the suggestion that the patient discontinue his buspirone since
the symptoms corresponded to the initiation of this drug.
The patient returned 11 days later having discontinued the buspirone, with no
change in symptoms or signs except that the left pupil now measured 1.5 mm larger
than the right pupil. Involvement of the left pupil was concerning; nevertheless, the
head CT results revealed no compressive lesions nor evidence of ischemia (Figure
1). Again, the patient was instructed on medication compliance and to contact the
clinic with worsening of symptoms. Six weeks later the patient returned to clinic
with both resolution of his left upper eyelid ptosis and restoration of superior gaze
of the left eye. Mild pupil asymmetry remained.
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Figure 1 Case 1 Head CT. Coronal, Transverse and Sagittal, respectively. Note no lesions of the
left superior orbit nor the cavernous sinus.

Discussion: Case 1
Medications affecting central nervous system activity, like buspirone, have been
reported to cause diplopia (Tables 1 and 2)5. Given the correlation of initiating
buspirone and the onset of a superior division ocular motor nerve palsy, followed
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by its resolution after discontinuing the buspirone, attributing the cause of the
transient neuropathy to buspirone use is reasonable. Furthermore, ischemia is the
most common cause of a CNIII palsy3. Buspirone can increase the blood pressure
lowering effects of blood pressure medications7. Since the patient was already
taking hydralazine (a vasodilator) and his lisinopril (an ACE inhibitor) was changed
to lisinopril-hydrochlorothiazide (a diuretic), the addition of buspirone may have
caused a rapid drop in blood pressure, resulting in ischemia as a contributing
causative factor of the partial third nerve palsy.7
Case 2
A 62-year-old white male presented to the emergency room complaining of
constant binocular diplopia, with associated diffuse headache, beginning earlier
that morning. The patient denied any other neurological symptoms or recent injury.
The patient’s medical history consisted of hypertension, hyperlipidemia, and
generalized anxiety disorder. His blood pressure was measured as 170/93 mmHg
in the ER. An in-patient head CT did not reveal evidence of cerebral vascular
accident nor a space occupying lesion (Figure 2). Neurology, consulted from the
ER, decided to admit the patient for further investigation of a stroke based on his
risk factors. An in-patient neurology examination revealed the following findings:
20/25 corrected vision OD-OS, right abduction deficit, bilateral direction changing
horizontal and rotary nystagmus in primary and lateral gazes with a vertical
nystagmus in down gaze and no reported null point were evident. At this point,
neurology was still concerned about a cerebral vascular accident (CVA) as the
etiology of the CN VI palsy. Therefore, daily Aspirin 325mg was prescribed, and a
brain MRI and head-neck MRA were ordered. Both the brain MRI and head-neck
MRA were negative for CVA and any compressive lesion (Figure 3, 4).
This individual was an established patient at the optometry clinic. So, three days
after he was discharged from the hospital, the patient presented to the optometry
clinic, as a self-referral, with recalcitrant symptoms of nystagmus and binocular
double vision. The patient’s last vision examination was seven months prior, which
reveal no ocular motility abnormalities. He stated compliance with the following
medications: amlodipine, aspirin, atorvastatin, hydroxyzine, melatonin (natural
hormone important for maintaining the biological clock; used off-label to treat
insomnia)7, mirtazapine, and propranolol. The patient believed his double vision
coincided with the initiation of zolpidem (Ambien) to treat his insomnia. Zolpidem
was not included in his active medication list, nor was zolpidem mentioned in the
ER/neurology note. Visual acuities were 20/20 OD-OS, confrontation visual fields
were full OD-OS, no pupil abnormalities were noted OU, and extraocular motility
testing revealed bilateral constant right jerk horizontal and rotational nystagmus
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that was worse in right and downward gaze, and a constant right hypertropia
(vertical diplopia was neutralized and single vision was reported with 22 prism
diopters of base-down prism OD in a trial frame). Intra-ocular pressures were
normal OU, biomicroscopy of the anterior segment and dilated fundus evaluation
were unremarkable OU (including no evident optic neuropathy), and H.R.R. color
vision was normal OD-OS. Static threshold visual fields revealed no evidence of
neurological defects OD-OS (Figure 5).

Figure 2 Case 2 Head CT; Coronal, Transverse and Sagittal, respectively. Note no lesions of right
lateral orbit nor cavernous sinus.
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Figure 3 Case 2 Brain MRI; Coronal, Transverse and Sagittal, respectively. Note, absence of
lesions of the right lateral orbit nor cavernous sinus.
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Figure 4 Case 2 Head-neck MRA. Note no lesions of the cavernous sinus nor circle of Willis.

Figure 5 Case 2 visual fields; left and right, respectively.
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Since the ocular alignment differed from the neurology assessment to this vision
exam, Myasthenia Gravis was a possible diagnosis. However, the patient was
adamant that his diplopia coincided with his initiating zolpidem. So, considering
the lack of evidence suggesting a cerebral infarction or a space occupying lesion
and with the absence of other neurological abnormalities (except for an associated
headache), the patient was treated with 25 prism diopter base-down Fresnel prism
to the right habitual spectacle lens. The neurologist was informed of the vision
examination results and provided with a copy of the visual field results.
Discontinuation of zolpidem was recommended. The patient was instructed to
contact the clinic if changes to neurological symptoms, vision or ocular comfort
occurred. Three weeks later, the patient returned for follow-up visit reporting
compliance with all medications, including discontinuation of zolpidem. Corrected
visual acuities measured 20/20 OD-OS, pupil testing remained unremarkable ODOS, no restriction of extraocular motility was noted, and confrontation visual fields
were still full OD-OS. While the bilateral nystagmus was still present (for which
the patient was asymptomatic), the right hypertropia and double vision were
resolved, such that the patient presented without the Fresnel prism on his spectacles.
Discussion: Case 2
Sedatives are one of the most common causes of nystagmus3. This patient was
taking multiple medications that affect CNS activity (Tables 1, and 2). By
excluding possible organic causes of the acute oculomotor dysfunction, it is
reasonable to surmise this patient reached his tolerance limit for medications
affecting the CNS activity.
DRUG CLASS
benzodiazepines

selective serotonin reuptake inhibitors

antidepressants
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DRUG EXAMPLES
alprazolam (Xanax)
clonazepam (KlonoPIN)
diazepam (Valium)
escitalopram (Lexapro)
lorazepam (Ativan)
duloxetine (Cymbalta)
paroxetine (Paxil)
venlafaxine (Effexor)
sertraline (Zoloft)
mirtazapine
trazodone
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DRUG CLASS

DRUG EXAMPLES

miscellaneous

buspirone/anti-anxiety
gabapentin
(Neurontin)/anti-epileptic
hydroxyzine/antihistamine
propranolol/beta-blocker

Table 1 Medications used to treat anxiety.7

DRUG CLASS
Antidepressants
Antihistamines
Benzodiazepines
Sedatives

DRUG EXAMPLES
amitriptyline
diphenhydramine
temazepam (Restoril)
eszopiclone (Lanesta), zolpidem (Ambien)

Table 2 Medications used to treat insomnia7. Notice the overlap with drugs used to treat anxiety.

Conclusion
Diplopia has been reported to occur following the initiation of central nervous
system affecting drugs with the diplopia resolving once the new medication was
discontinued1,6. Hence, obtaining an adequate patient medical and ocular history
when confronted with new onset diplopia or nystagmus is imperative for good
clinical care. As exhibited by the presented cases, the potential for drug side effects
and interactions to be the etiology of a new onset oculomotor dysfunction may be
suspected, particularly with medications that affect blood pressure and central
nervous system functions (Tables 1 and 2).
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